EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Optimizing the Dosing Regimen of Cetuximab and Ramucirumab Using the Model‐Informed Drug Development Paradigm

Lan Ni, Azhar Zaman Khan, Amanda Long, Ling Gao, Nikki Toms, Elena Gonzalez-Gugel, Susan Holsmer-Brand, Yong Lin, Paolo Abada, Sandra Dickin, Declan O'Dea, Ran Wei und 2 weitere

Clinical Pharmacology & Therapeutics · 2023

DOI: 10.1002/cpt.2919 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, 2023. Verfasst von Lan Ni und 13 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Drug Development. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Model‐informed drug development (MIDD) is a process that integrates drug exposure‐based, biological, and statistical models to enhance the benefit–risk balance in drug development. The US Food and Drug Administration (FDA) MIDD Paired Meeting Pilot Program provides a platform to apply MIDD approaches to drug development and to seek regulatory feedback in a collaborative and streamlined process prior to submission for approval. Eli Lilly and Company (Lilly) participated in the Pilot Program to seek agency alignment to enhance the initial approved dosing regimens of cetuximab (Erbitux; Eli Lilly and Company, Indianapolis, IN) and ramucirumab (Cyramza; Eli Lilly and Company) without conducting additional clinical trials. Here, we describe the overall MIDD strategy at Lilly, the process with the FDA, and the impact of implementing the approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedDrug DevelopmentHumansPharmaceutical PreparationsCetuximabRamucirumab

Substanzen

Pharmaceutical PreparationsCetuximabAntibodies, Monoclonal, HumanizedRamucirumab

Autor:innen und Institutionen

  • Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Taiho Oncology Inc., Princeton, New Jersey, USA.
  • Merck & Co., Inc., Kenilworth, New Jersey, USA.

ORCID-Profile: Min-Hua Jen

Zitieren

APA

Ni, L., Khan, A. Z., Long, A., Gao, L., Toms, N., Gonzalez-Gugel, E., Holsmer-Brand, S., Lin, Y., Abada, P., Dickin, S., O'Dea, D., Wei, R., Jen, M. H., & Aggarwal, H. (2023). Optimizing the Dosing Regimen of Cetuximab and Ramucirumab Using the Model‐Informed Drug Development Paradigm. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.2919

Vancouver

Ni L, Khan AZ, Long A, Gao L, Toms N, Gonzalez-Gugel E, et al. Optimizing the Dosing Regimen of Cetuximab and Ramucirumab Using the Model‐Informed Drug Development Paradigm. Clinical Pharmacology & Therapeutics. 2023. doi:10.1002/cpt.2919

BibTeX
@article{Ni2023,
  author = {Ni, Lan and Khan, Azhar Zaman and Long, Amanda and Gao, Ling and Toms, Nikki and Gonzalez-Gugel, Elena and Holsmer-Brand, Susan and Lin, Yong and Abada, Paolo and Dickin, Sandra and O'Dea, Declan and Wei, Ran and Jen, Min-Hua and Aggarwal, Himani},
  title = {Optimizing the Dosing Regimen of Cetuximab and Ramucirumab Using the Model‐Informed Drug Development Paradigm},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2023},
  doi = {10.1002/cpt.2919}
}
Kostenlos starten →